Catalent (CTLT) Misses Q4 EPS by 1c, FY17 Revenue Guidance Tops Views at Mid-Point
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Catalent, Inc. Reports Fourth Quarter and Fiscal Year 2016 Results
August 29, 2016 4:15 PM EDTQ4'16 revenue $532.2 million increased 6% in constant currency from the prior year period FY'16 revenue of $1.85 billion increased 6% in constant currency from the prior year period Catalent's proprietary OptiShell softgel technology has been selected for use in OPKO Health's NDA for RAYALDEE® and has been approved by the U.S. FDA Announced the launch of our FastChain service, for greater speed, flexibility and efficiency in the management and distribution of global clinical trial supplies... More
